Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1946 1
1947 1
1949 3
1951 1
1952 1
1955 3
1956 2
1957 3
1959 3
1960 2
1961 2
1962 2
1963 1
1964 1
1965 3
1966 6
1967 11
1968 2
1969 1
1970 4
1971 5
1972 8
1973 7
1974 13
1975 26
1976 25
1977 33
1978 27
1979 24
1980 25
1981 19
1982 16
1983 22
1984 20
1985 15
1986 14
1987 48
1988 62
1989 100
1990 102
1991 125
1992 105
1993 106
1994 123
1995 134
1996 157
1997 160
1998 198
1999 191
2000 304
2001 385
2002 392
2003 461
2004 571
2005 623
2006 678
2007 813
2008 827
2009 967
2010 1272
2011 1472
2012 1699
2013 1709
2014 1969
2015 2174
2016 3138
2017 4484
2018 5505
2019 7376
2020 11096
2021 16491
2022 18324
2023 19718
2024 21330
2025 24931
2026 6778
2027 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140,406 results

Results by year

Filters applied: . Clear all
Page 1
Pfizer's vaccine raises allergy concerns.
de Vrieze J. de Vrieze J. Science. 2021 Jan 1;371(6524):10-11. doi: 10.1126/science.371.6524.10. Science. 2021. PMID: 33384356 No abstract available.
Respiratory Syncytial Virus Infection: An Update.
Soni A, Kabra SK, Lodha R. Soni A, et al. Indian J Pediatr. 2023 Dec;90(12):1245-1253. doi: 10.1007/s12098-023-04613-w. Epub 2023 Jun 16. Indian J Pediatr. 2023. PMID: 37326948 Review.
The US FDA has approved two RSV vaccines for use in older adults (GSK's Arexvy and Pfizer's ABRYSVO)....
The US FDA has approved two RSV vaccines for use in older adults (GSK's Arexvy and Pfizer's ABRYSVO)....
Fixing the Achilles Heel of Pfizer's Paxlovid for COVID-19 Treatment.
Brewitz L, Schofield CJ. Brewitz L, et al. J Med Chem. 2024 Jul 25;67(14):11656-11661. doi: 10.1021/acs.jmedchem.4c01342. Epub 2024 Jul 5. J Med Chem. 2024. PMID: 38967233 Free PMC article. Review.
Nirmatrelvir (PF-07321332), a first-in-class inhibitor of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) main protease (M(pro)), was developed by Pfizer under intense pressure during the pandemic to treat COVID-19. A weakness of nirmatrelvir is its limite …
Nirmatrelvir (PF-07321332), a first-in-class inhibitor of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) main protease (M( …
Diagnosis, Genetics, and Therapy of Short Stature in Children: A Growth Hormone Research Society International Perspective.
Collett-Solberg PF, Ambler G, Backeljauw PF, Bidlingmaier M, Biller BMK, Boguszewski MCS, Cheung PT, Choong CSY, Cohen LE, Cohen P, Dauber A, Deal CL, Gong C, Hasegawa Y, Hoffman AR, Hofman PL, Horikawa R, Jorge AAL, Juul A, Kamenický P, Khadilkar V, Kopchick JJ, Kriström B, Lopes MLA, Luo X, Miller BS, Misra M, Netchine I, Radovick S, Ranke MB, Rogol AD, Rosenfeld RG, Saenger P, Wit JM, Woelfle J. Collett-Solberg PF, et al. Horm Res Paediatr. 2019;92(1):1-14. doi: 10.1159/000502231. Epub 2019 Sep 12. Horm Res Paediatr. 2019. PMID: 31514194 Free PMC article. Review.
Comparing Moderna's mRNA-1083 and Pfizer's dual-target mRNA vaccines for influenza and COVID-19.
Akingbola A, Adegbesan A, Adegoke K, Idahor C, Mariaria P, Peters F, Salami RA, Ojo O, Nwaeze E, Abdullahi O, Chuku J. Akingbola A, et al. NPJ Vaccines. 2025 May 24;10(1):105. doi: 10.1038/s41541-025-01145-6. NPJ Vaccines. 2025. Retraction in: NPJ Vaccines. 2025 Dec 24;10(1):265. doi: 10.1038/s41541-025-01353-0. PMID: 40413212 Free PMC article. Retracted. Review.
This review examines Moderna's mRNA-1083 and Pfizer/BioNTech's mRNA-1020/1030 dual-target vaccines for COVID-19 and influenza. Both utilize mRNA technology, demonstrating strong immunogenicity and favorable safety profiles. Moderna's mRNA-1083 showed superior immune respon …
This review examines Moderna's mRNA-1083 and Pfizer/BioNTech's mRNA-1020/1030 dual-target vaccines for COVID-19 and influenza. Both u …
The journey of a lifetime - development of Pfizer's COVID-19 vaccine.
Thorn CR, Sharma D, Combs R, Bhujbal S, Romine J, Zheng X, Sunasara K, Badkar A. Thorn CR, et al. Curr Opin Biotechnol. 2022 Dec;78:102803. doi: 10.1016/j.copbio.2022.102803. Epub 2022 Sep 1. Curr Opin Biotechnol. 2022. PMID: 36162187 Free PMC article. Review.
It would be apt to say that one of the greatest accomplishments in modern medicine has been the development of vaccines against COVID-19, which had paralyzed the entire world for more than a year. Pfizer and BioNTech codeveloped the first COVID-19 vaccine that was granted …
It would be apt to say that one of the greatest accomplishments in modern medicine has been the development of vaccines against COVID-19, wh …
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.
Rugo HS, Finn RS, Diéras V, Ettl J, Lipatov O, Joy AA, Harbeck N, Castrellon A, Iyer S, Lu DR, Mori A, Gauthier ER, Bartlett CH, Gelmon KA, Slamon DJ. Rugo HS, et al. Breast Cancer Res Treat. 2019 Apr;174(3):719-729. doi: 10.1007/s10549-018-05125-4. Epub 2019 Jan 10. Breast Cancer Res Treat. 2019. PMID: 30632023 Free PMC article. Clinical Trial.
These data confirm that palbociclib-letrozole should be considered the standard of care for first-line therapy in patients with ER+/HER2- ABC, including those with low disease burden or long disease-free interval. Sponsored by Pfizer; ClinicalTrials.gov: NCT01740427....
These data confirm that palbociclib-letrozole should be considered the standard of care for first-line therapy in patients with ER+/HER2- AB …
Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024.
Moline HL, Toepfer AP, Tannis A, Weinberg GA, Staat MA, Halasa NB, Boom JA, Klein EJ, Williams JV, Schuster JE, Goldstein L, McKeever ER, Kalman C, Paden C, Atherton L, Aggarwal M, Roychoudhury P, Piedra PA, Sahni LC, Stewart LS, Selvarangan R, Michaels MG, Schlaudecker EP, Szilagyi PG, Englund JA, Clopper BR, Thornburg NJ, Derado G, McMorrow ML, Dawood FS; New Vaccine Surveillance Network Collaborators. Moline HL, et al. JAMA Pediatr. 2025 Feb 1;179(2):179-187. doi: 10.1001/jamapediatrics.2024.5572. JAMA Pediatr. 2025. PMID: 39652359 Free PMC article.
IMPORTANCE: During the 2023-2024 respiratory syncytial virus (RSV) season in the United States, 2 new RSV prevention products were recommended to protect infants in their first RSV season: nirsevimab and Pfizer's maternal RSV vaccine. Postlicensure studies are neede …
IMPORTANCE: During the 2023-2024 respiratory syncytial virus (RSV) season in the United States, 2 new RSV prevention products were recommend …
Pfizer's puzzle.
Simons J. Simons J. Fortune. 2006 Apr 17;153(7):152-4, 156. Fortune. 2006. PMID: 16649633 No abstract available.
140,406 results
You have reached the last available page of results. Please see the User Guide for more information.